Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

Dicerna Pharma Form 4	ceuticals Inc									
April 18, 2014	-									
FORM 4	UNITED	STATES	SECUI	RITIES A	AND EX	CHANGE	COMMISSIO		APPROVAL	
Check this box Washington, D.								3235-0287		
if no longer subject to Section 16. Form 4 or	F CHANGES IN BENEFICIAL OW SECURITIES					Estimated burden hol response	urs per			
Form 5 obligations may continue <i>See</i> Instructio 1(b).	Section 17(a) of the	Public U	tility Hol	ding Cor		nge Act of 1934 of 1935 or Sect 940			
(Print or Type Resp	onses)									
1. Name and Address of Reporting Person <u>*</u> Halak Brian K			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer			
			Dicerna Pharmaceuticals Inc [DRNA]				(Check all applicable)			
(Last) (First) (Middle) C/O DOMAIN ASSOCIATES, LLC, ONE PALMER SQUARE			3. Date of Earliest Transaction (Month/Day/Year) 04/16/2014			X_DirectorX_10% Owner Officer (give titleOther (specify below) below)				
(Street) PRINCETON, NJ 08542			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 				
(City)	(State)	(Zip)	Tah	le I - Non-l	Derivative	Securities A	.cquired, Disposed	of. or Beneficia	ally Owned	
	ransaction Date nth/Day/Year)	Execution any	ed Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit mAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
		c 1 1								
Reminder: Report o	n a separate line	e for each cl	lass of sec	urities bene	Perso inforn requir	ns who res nation cont red to respo nys a currer	prindirectly. Spond to the colle ained in this forr ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)	
	Tab					posed of, or convertible s	Beneficially Owne securities)	d		
1. Title of 2.	3. Trans	saction Date	e 3A. Dee	emed	4.	5. Number	of 6. Date Exerc	isable and	7. Title and Amount of 8	

Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative

Expiration Date

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(A) ed of			(Instr. 3 and 4)		5
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 16.3	04/16/2014		А	25,000		<u>(1)</u>	01/30/2024	Common Stock	25,000	

Reporting Owners

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
Halak Brian K C/O DOMAIN ASSOCIATES, LLC ONE PALMER SQUARE PRINCETON, NJ 08542	Х	Х				
Signatures						
/s/Kathleen K. Schoemaker, Attorney-in-Fact		04/18/20	14			
**Signature of Reporting Person		Date				
Evelopetion of Deepe		_				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in 36 equal monthly installments on the last day of each month beginning on January 31, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (